Evidence from Experience: Unity in Diversity

Authors

  • Sanjay Kalra Dept. of Endocrinology, Bharti Hospital, Karnal, Haryana, India
  • Navneet Agrawal Dept. of Diabetology, Diabetes Obesity Thyroid Centre, Gwalior, Madhya Pradesh, India
  • Rakesh Sahay Dept. of Endocrinology, Osmania Medical College, Hyderabad, Telangana, India

Keywords:

Co-formulation insulin, diabetes, FDC, glimepiride, India, insulin, IDegAsp, type 2 diabetes

Abstract

Diabetes in India presents unique challenges, which merit bespoke solutions. The early onset and rapid progression of diabetes, along with late presentation to the healthcare system, call for more proactive management strategies. At the same time, persons living with diabetes ask for convenient, uncomplicated treatment regimens, which offer comprehensive control with minimal dose frequency. The original research published in this issue highlights the relevance of fixed-dose combinations (FDCs) of sulfonylurea and metformin, as well as fixed-ratio combinations (FRCs) of rapid-acting and long-acting insulin analogs, in diabetes care. In this editorial, we highlight the similar preferences of oral and insulin medication, and explore the rationale behind this. We hope that this insight will encourage further discussion and research on ethnocentric pharmacotherapy in diabetology.

Additional Files

Published

2022-10-21

Issue

Section

Editorial

Similar Articles

1-10 of 80

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 > >>